Related Experiment Video

Updated: Dec 13, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.8K

Prediction of Cirrhosis in Patients with Chronic Hepatitis C by Genotype 3

Tarana Gupta1, Hari K Aggarwal1, Sandeep Goyal2

  • 1Department of Medicine, Post Graduate Institute of Medical Sciences, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India.

Euroasian Journal of Hepato-Gastroenterology
|August 4, 2020
PubMed

Insights

Hepatitis C virus (HCV) genotype 3 is linked to increased liver fibrosis and cirrhosis. However, decompensation rates did not differ between genotype 3 and other HCV genotypes in this study.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Chronic hepatitis C (CHC) is a significant cause of liver disease worldwide.
  • Hepatitis C virus (HCV) genotype 3 is known to be associated with more severe liver fibrosis.
  • Understanding the impact of HCV genotype on disease progression is crucial for patient management.

Purpose of the Study:

  • To investigate the influence of HCV genotype 3 on the prevalence and severity of liver disease in CHC patients.
  • To compare liver disease markers between patients with HCV genotype 3 and other genotypes.
  • To assess the association between HCV genotype and the development of cirrhosis.

Main Methods:

  • A study cohort of 949 individuals with positive anti-HCV antibodies was analyzed.
  • Patients were categorized into genotype 3 and non-genotype 3 groups.
  • Liver stiffness measurement (transient elastography), biochemical parameters (AST), platelet counts, and HCV RNA load were compared.

Main Results:

  • Genotype 3 patients exhibited higher liver stiffness (fibrosis) and AST levels compared to non-genotype 3 patients.
  • A significantly higher prevalence of cirrhosis was observed in the genotype 3 group.
  • Despite increased fibrosis and cirrhosis, decompensation rates were similar between the groups.

Conclusions:

  • HCV genotype 3 is associated with a greater degree of liver fibrosis and a higher prevalence of cirrhosis in CHC.
  • While genotype 3 promotes fibrosis, it does not appear to increase the risk of liver decompensation compared to other genotypes.
  • Further research may explore mechanisms driving fibrosis in genotype 3 and strategies for preventing cirrhosis progression.
Abstract

Keywords:
Chronic hepatitis CCirrhosisFibrosisGenotypeTransient elastography

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.1K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
107
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133